MedTrace Logo

A Long-Term Study in Schizophrenia

NCT01487083 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 282

Last updated 2013-01-21

No results posted yet for this study

Summary

The purpose of this study is to evaluate the long-term safety of pomaglumetad methionil in participants with schizophrenia.

Conditions

Interventions

DRUG

Pomaglumetad methionil

Administered orally

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • United States
  • Austria
  • Brazil
  • France
  • Germany
  • Greece
  • Poland
  • Puerto Rico
  • Romania
  • Spain
  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01487083 on ClinicalTrials.gov